Live INNOVENT price
INNOVENT price chart
INNOVENT (INNOVENT) price details
INNOVENT price history
INNOVENT technical analysis

INNOVENT (INNOVENT) sentiment
About INNOVENT
Innovent Biologics is a prominent biopharmaceutical company dedicated to developing, manufacturing, and commercializing high-quality medicines for oncology, metabolic, and autoimmune diseases. The firm boasts a robust pipeline of innovative monoclonal antibodies and fusion proteins designed to meet global medical standards. Innovent focuses on making advanced, premium-grade biologics accessible and affordable to patients worldwide.
Official links
Social media and community
FAQ
1. What is the current price of INNOVENT (INNOVENT) in USD?
2. What is the market capitalization of INNOVENT (INNOVENT)?
3. What is the circulating supply of INNOVENT (INNOVENT)?
4. What factors influence the price of INNOVENT (INNOVENT)?
5. Is INNOVENT (INNOVENT) a good investment?
6. Where can I buy INNOVENT (INNOVENT)?
7. What are the typical fees when buying INNOVENT (INNOVENT)?
8. What are some technical indicators used for analyzing INNOVENT (INNOVENT)?
Currency price converter
Popular
How to buy
INNOVENT news
Firedancer makes bounty hunters burn 1 SOL even for duplicate bug reports
Firedancer requires a non-refundable 1 SOL burn for bug-bounty eligibility, even for duplicates. Later reports can still earn discretionary rewards.
Interpol: 1,462 Arrests and Crypto Money Laundering Networks Dismantled in Africa
NYSE’s owner is backing 24/7 stock tokens without Wall Street’s usual price rules
NYSE owner ICE backs OKXICE's 24/7 stock token plans as 16 issuers object and automated liquidity pools raise pricing issues.
Bitcoin Hashrate Reclaims One Zettahash As Mining Competition Rebounds
Will Anthropic Delay Its 'Super IPO' Amid AI Trading Collapse? The Scheduled Listing Date in Mid-November Approaches
The time window is extremely tight—according to SEC regulations, the S-1 filing must be submitted by next week at the latest, with market predictions giving an 80% chance of an IPO this year. The AI sector's sell-off casts a shadow over the IPO prospects, as a previous plan for a September listing h...












